1. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. (November 2018) Authors: Veenstra, V.; Damhofer, H.; Waasdorp, C.; Rijssen, L.; Vijver, M.; Dijk, F.; Wilmink, H.; Besselink, M.; Busch, O.; Chang, D.; Bailey, P.; Biankin, A.; Kocher, H.; Medema, J.; Li, J.; Jiang, R.; Pierce, D.; Laarhoven, H.; Bijlsma, M. Journal: Oncogenesis Issue: Volume 7(2018:Nov.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy. (1st April 2022) Authors: Fenstermacher, M. E.; Abbate, J.; Abe, S.; Abrams, T.; Adams, M.; Adamson, B.; Aiba, N.; Akiyama, T.; Aleynikov, P.; Allen, E.; Allen, S.; Anand, H.; Anderson, J.; Andrew, Y.; Andrews, T.; Appelt, D.; Arbon, R.; Ashikawa, N.; Ashourvan, A.; Aslin, M. Journal: Nuclear fusion Issue: Volume 62:Number 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗